BioVersys
Switching Off Bacterial Resistance

BIO 2016
Global Workshop for Novel Anti-Infectives

Contact details:
Tel.: +41 (0)61 633 22 50
Mobile: +41 (0)79 822 57 16
Mail: marc.gitzinger@bioversys.com
TRIC therapeutics for antimicrobial therapy

**Transcription Regulator Inhibitory Compounds**

Resistant mechanisms

*Resistance mechanism OFF*

*Antibiotic kills again*

*Biofilm/virulence is repressed*

*Biofilm/virulence expressed*

*Essential metabolic function*

*External stimulus*
Resistance reversed + shift of treatment regimen

Resistance fully reverted

<table>
<thead>
<tr>
<th>MDR Clinical Strain ID</th>
<th>MIC ETH</th>
<th>MIC ETH + TRIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>B1602</td>
<td>256</td>
<td>0,5</td>
</tr>
<tr>
<td>B1304</td>
<td>256</td>
<td>0,5</td>
</tr>
<tr>
<td>B1196</td>
<td>256</td>
<td>0,25</td>
</tr>
<tr>
<td>B1166</td>
<td>64</td>
<td>0,25</td>
</tr>
<tr>
<td>B1150</td>
<td>64</td>
<td>0,05</td>
</tr>
<tr>
<td>B1099</td>
<td>64</td>
<td>0,25</td>
</tr>
<tr>
<td>B1004</td>
<td>32</td>
<td>0,25</td>
</tr>
<tr>
<td>B1001</td>
<td>32</td>
<td>0,05</td>
</tr>
<tr>
<td>B0775</td>
<td>32</td>
<td>0,025</td>
</tr>
<tr>
<td>B0467</td>
<td>32</td>
<td>0,5</td>
</tr>
<tr>
<td>B0391</td>
<td>16</td>
<td>0,05</td>
</tr>
<tr>
<td>B0383</td>
<td>16</td>
<td>0,1</td>
</tr>
<tr>
<td>B0089</td>
<td>8</td>
<td>0,5</td>
</tr>
<tr>
<td>B0057</td>
<td>8</td>
<td>0,25</td>
</tr>
<tr>
<td>L1094</td>
<td>2</td>
<td>0,05</td>
</tr>
<tr>
<td>H37Rv</td>
<td>1</td>
<td>0,05</td>
</tr>
</tbody>
</table>

ETH: ethionamide
MIC: minimal inhibitory concentration
MDR: multi-drug resistant

Work performed in collaboration with Profs: Baulard, Deprez and Willand from the Institut Pasteur Lille and GSK

Lead properties:
- nM efficacy
- 100% of isolates susceptible
- Oral bioavailability
- Good pK profile
- Clean tox profile
- Efficacy in mice: <10mg/kg

• 7 x less Ethionamide needed
• Increasing drug exposure might result in shortened treatment time
Pipeline 2016 – onwards

2017 2018 2019 2020 2021

TB
- Reverting resistance in MDR/XDR TB
  TRIC-NCE + ethionamide

Gram-positives
- Tuning down biofilm formation and virulence in staphylococci
  TRIC-NCE alone or in combination with an antibiotic

Gram-negatives
- Tuning down virulence factors in enterobacteriaceae
  TRIC-NCE alone or in combination with an antibiotic
- Essential target in Acinetobacter baumannii
  TRIC-NCE alone

- Lead Selection + Supporting Biology
- Lead Optimisation + PoC in animals
- Preclinical Development
- Phase 1
- PoC in human
- Phase 1
- PoC in human
- Phase 1
- PoC in human
- Phase 3
- Proof of Concept in Humans
- Conditional approval
Thank you for your attention
and
Please contact us for further information

www.bioversys.com

Contact details:
Marc Gitzinger
Tel.: +41 (0)61 633 22 50
Mobile: +41 (0)79 822 57 16
Mail: marc.gitzinger@bioversys.com